Dakshnapriya Balasubbramanian

Dr. Dakshnapriya Balasubbramanian


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BGBethany Goodlett
Bethany Goodlett
CKChang Sun Kang
Chang Sun Kang
EYEunsoo Yoo
Eunsoo Yoo
SNShobana Navaneethabalakrishnan
Shobana Navaneethabalakrishnan
DBDakshnapriya Balasubbramanian
Dakshnapriya Balasubbramanian
Brett M MitchellBrett M Mitchell
Brett M Mitchell
Chronic interstitial inflammation and renal infiltration of activated immune cells play an integral role in hypertension. Lymphatics regulate inflammation through clearance of immune cells and excess interstitial fluid. Previously, we demonstrated increasing renal lymphangiogenesis prevents hypertension in mice. We hypothesized that targeted nanoparticle delivery of vascular endothelial growth factor-C (VEGF-C) to the kidney would induce renal lymphangiogenesis, lowering blood pressure in hypertensive mice. A kidney-targeting nanoparticle was loaded with a VEGF receptor-3-specific form of VEGF-C and injected into mice with angiotensin II-induced hypertension or LNAME-induced hypertension every 3 days. Nanoparticle-treated mice exhibited increased renal lymphatic vessel density and width compared to hypertensive mice injected with VEGF-C alone. Nanoparticle-treated mice exhibited decreased systolic blood pressure, decreased pro-inflammatory renal immune cells, and increased urinary fractional excretion of sodium. Our findings demonstrate that pharmacologically expanding renal lymphatics decreases blood pressure and is associated with favorable alterations in renal immune cells and increased sodium excretion.